Biotech Firm Azitra Denies $44mln Direct Offering Report, Stock Plummets 19% in Pre-Market Trading

Azitra denies a report of a $44 million direct offering, stating the report is "false and should not be relied upon." The company urges investors to rely only on information formally issued through official channels. Shares fell nearly 19% in premarket trading. Azitra is investigating the source of the false report.